• Explore /
  • Poster
  • / A phase 1 trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors.

A phase 1 trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors.

Abstract Video & Slides Poster

Authors

Philippe Bedard

Philippe L. Bedard

Princess Margaret Cancer Centre, Toronto, ON, Canada

Philippe L. Bedard , Alberto Hernando-Calvo , Richard D. Carvajal , Van K. Morris II, Paul K. Paik , Dan Paul Zandberg , John M. Kaczmar , Liviu Niculescu , David Bohr , Ralf Reiners , Elham Gharakhani , Rachel Salazar , Sanela Bilic , Glenn J. Hanna

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Antibodies

Clinical Trial Registration Number

NCT04429542

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 2513)

DOI

10.1200/JCO.2022.40.16_suppl.2513

Abstract #

2513

Poster Bd #

169

Abstract Disclosures

Similar Posters

First Author: Iwona A. Lugowska

First Author: Naiyer A. Rizvi

First Author: Judy S. Wang

First Author: Anwaar Saeed